Q3 2017 EPS Estimates for Antares Pharma, Inc. Increased by Analyst (ATRS)

Antares Pharma, Inc. (NASDAQ:ATRS) – Stock analysts at Jefferies Group lifted their Q3 2017 earnings estimates for Antares Pharma in a research report issued on Tuesday. Jefferies Group analyst A. Petrone now forecasts that the specialty pharmaceutical company will post earnings of ($0.03) per share for the quarter, up from their prior estimate of ($0.04). Jefferies Group also issued estimates for Antares Pharma’s Q4 2017 earnings at ($0.02) EPS, FY2017 earnings at ($0.09) EPS and FY2018 earnings at ($0.07) EPS.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. The company had revenue of $13.42 million for the quarter, compared to analysts’ expectations of $12.99 million.

ILLEGAL ACTIVITY NOTICE: This article was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/2801312/q3-2017-eps-estimates-for-antares-pharma-inc-increased-by-analyst-atrs.html.

ATRS has been the topic of several other reports. Vetr upgraded Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target on the stock in a research report on Wednesday, July 5th. Chardan Capital began coverage on Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Antares Pharma in a research report on Friday, June 23rd. Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Raymond James Financial, Inc. began coverage on Antares Pharma in a research report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 price target on the stock. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $3.83.

Antares Pharma (ATRS) opened at 2.87 on Friday. The company’s market cap is $448.89 million. Antares Pharma has a 52-week low of $1.01 and a 52-week high of $3.37. The firm has a 50-day moving average price of $3.15 and a 200-day moving average price of $2.76.

In related news, insider Fred M. Powell purchased 130,000 shares of Antares Pharma stock in a transaction that occurred on Friday, June 9th. The shares were acquired at an average cost of $2.79 per share, for a total transaction of $362,700.00. Following the transaction, the insider now directly owns 331,434 shares in the company, valued at $924,700.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.60% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of ATRS. Alliancebernstein L.P. bought a new position in Antares Pharma during the second quarter valued at about $119,000. Legal & General Group Plc bought a new position in Antares Pharma during the second quarter valued at about $120,000. Credit Suisse AG bought a new position in Antares Pharma during the first quarter valued at about $146,000. National Planning Corp raised its position in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares during the last quarter. Finally, KCG Holdings Inc. raised its position in Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares during the last quarter. Institutional investors and hedge funds own 31.70% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.